Specialized IRB niche Castle IRB focuses on protective oversight for gene and cell therapy clinical trials, presenting a clear value proposition for sponsors seeking experienced, ethics-forward review for advanced therapies.

Boutique scale advantage With a lean team from 2 to 10 employees, Castle IRB can offer personalized service and rapid turnaround times that larger IRBs may struggle to match, appealing to agile biotech startups and niche trials.

Growth opportunity gaps Revenue under one million and smaller headcount indicate potential for scalable service packages, strategic partnerships, and tiered pricing to capture larger or multi-site trials as they expand.

Competitive positioning Positioned among larger, established IRBs (Advarra, Quorum/WCG) but with a specialization in gene and cell therapy, Castle IRB can target sponsors seeking domain expertise and a hands-on review approach.

Strategic partnerships There is an opportunity to form alliances with gene/cell therapy CROs, academic networks, and biotech accelerators to source trials, share resources, and accelerate onboarding for new clients.